Surgery Partners Files 8-K

TL;DR

Surgery Partners filed an 8-K on 12/11/25. Standard disclosure.

AI Summary

Surgery Partners, Inc. filed an 8-K on December 11, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing details the company's principal executive offices located at 340 Seven Springs Way, Suite 600, Brentwood, Tennessee, 37027, and its telephone number is (615) 234-5900. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This 8-K filing serves as an official notification to the SEC and the public regarding important company events and financial disclosures for Surgery Partners, Inc.

Risk Assessment

Risk Level: low — This filing is a routine 8-K for corporate disclosures and does not appear to contain any material adverse information.

Key Players & Entities

• Surgery Partners, Inc. (company) — Registrant
• December 11, 2025 (date) — Date of earliest event reported
• 340 Seven Springs Way, Suite 600, Brentwood, Tennessee, 37027 (address) — Address of Principal Executive Offices
• 615-234-5900 (phone_number) — Registrant's telephone number
• Delaware (jurisdiction) — State of Incorporation
• 1231 (fiscal_year_end) — Fiscal Year End

FAQ

Key Financial Figures

• $0.01 — h registered Common Stock, par value $0.01 per share SGRY The Nasdaq Global Sele
• $425.0 million — , Inc. (the "Issuer"), intends to offer $425.0 million of additional 7.250% Senior Notes due 2

Filing Documents

• tm2533207d1_8k.htm (8-K) — 27KB
• tm2533207d1_ex99-1.htm (EX-99.1) — 7KB
• tm2533207d1_ex99-1img001.jpg (GRAPHIC) — 4KB
• 0001104659-25-120159.txt ( ) — 206KB
• sgry-20251211.xsd (EX-101.SCH) — 3KB
• sgry-20251211_lab.xml (EX-101.LAB) — 33KB
• sgry-20251211_pre.xml (EX-101.PRE) — 22KB
• tm2533207d1_8k_htm.xml (XML) — 4KB

01

Item 7.01 Regulation FD Disclosure. On December 11, 2025, Surgery Partners, Inc. ("Surgery Partners" or the "Company") announced that its wholly-owned subsidiary, Surgery Center Holdings, Inc. (the "Issuer"), intends to offer $425.0 million of additional 7.250% Senior Notes due 2032 (the "Offering"), the proceeds of which are expected to be used for general corporate purposes, including, but not limited to, repaying outstanding borrowings under its revolving credit facility. The Offering is expected to be conducted pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the "Securities Act"). The Company issued a press release with respect to the Offering, and such press release is attached hereto and furnished as Exhibit 99.1. The information in this Item 7.01 and in the accompanying exhibit is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Registrant under the Securities Act or the Exchange Act.

Forward-Looking Statements

Forward-Looking Statements This report contains "forward-looking" statements, including those regarding Surgery Partners' intention to offer and sell, and apply the net proceeds of, the notes. These statements include, but are not limited to, the Company's expectations regarding the proposed offering. These statements can be identified by the use of words such as "believes," "anticipates," "expects," "intends," "plans," "continues," "estimates," "predicts," "projects," "forecasts," and similar expressions. All forward-looking statements are based on current expectations and beliefs as of the date of this report and are subject to risks, uncertainties and other factors that may cause actual results to differ materially from the expectations discussed in, or implied by, the forward-looking statements. Many of these factors are beyond our ability to control or predict including, without limitation, the risk that the proposed offering is not completed on the terms or in the amounts anticipated, or at all, and the other risks and uncertainties identified and discussed in the Company's reports filed with the SEC, including in Item 1A under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 7, 2025 and the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, filed on May 12, 2025, August 5, 2025 and November 10, 2025, respectively. Except as required by law, neither the Company nor the Issuer undertakes any obligation to revise or update publicly any forward-looking statements to reflect events or circumstances after the date of this report, or to reflect the occurrence of unanticipated events or circumstances.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99. 1 Press Release, dated December 11, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 11, 2025 SURGERY PARTNERS, INC. By: /s/ David T. Doherty David T. Doherty Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR